Coeptis Therapeutics Holdings, Inc.

COEP Nasdaq CIK: 0001759186

Company Information

Industry Finance Services
SIC Code 6199
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 105 BRADFORD ROAD, SUITE 420, WEXFORD, PA, 15090
Mailing Address 105 BRADFORD ROAD, SUITE 420, WEXFORD, PA, 15090
Phone 724-934-6467
Fiscal Year End 1231
EIN 981465952

Financial Overview

FY2024

$8.91M
Total Assets
$814K
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
8-K Current report of material events February 12, 2026 View on SEC

Material Events

8-K Strategy Change February 4, 2026
High Impact
  • Merger with Z Squared Technologies creates a diversified healthcare technology leader focused on AI-driven analytics and digital therapeutics.
  • Retains promising GEAR Therapeutics CAR T-cell therapy platform, signaling a strategic focus on high-potential, cutting-edge therapies.
View Analysis
8-K Legal Issue January 16, 2026
High Impact
  • Coeptis Therapeutics received a warning letter from Nasdaq for non-compliance, specifically for failing to hold its annual shareholder meeting within the required timeframe.
  • The company's fiscal year ended on December 31, 2024, and the annual meeting was not held by the deadline.
View Analysis

Related Companies

Companies in the same industry (SIC: 6199)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.